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Abstract
Purpose Bovine colostrum is available in health food shops and as a sports food supplement and is rich in antibodies and 
growth factors including IGF-1. World Anti-Doping Agency advises athletes against taking colostrum for fear of causing 
increased plasma IGF-1. There are also concerns that colostrum may theoretically stimulate malignancy in organs which 
express IGF-1 receptors. We, therefore, determined changes in plasma IGF-1 levels in subjects taking colostrum or placebo 
for 1 day, 4 weeks, and 12 weeks.
Methods Plasma IGF1 levels were determined in healthy males (n = 16) who ingested 40 g bovine colostrum or placebo 
along with undertaking moderate exercise for total period of 4.5 h. Two further studies followed changes in IGF1 using 
double-blind, parallel group, placebo-controlled, randomized trials of colostrum or placebo (N = 10 per arm, 20 g/day for 
4 weeks and N = 25 colostrum, N = 29 placebo arm 20 g/day for 12 weeks).
Results Baseline IGF1 levels 130 ± 36 ng/ml. 4.5 h protocol showed no effect of colostrum on plasma IGF1 (ANOVA, 
treatment group: p = 0.400, group × time: p = 0.498, time p = 0.602). Similarly, no effect of colostrum ingestion was seen 
following 4 week (ANOVA, group: p = 0.584, group × time interaction: p = 0.083, time p = 0.243) or 12 week (ANOVA, 
group: p = 0.400, group × time interaction: p = 0.498, time p = 0.602) protocol.
Conclusions Ingestion of standard recommended doses of colostrum does not increase IGF-1 levels in healthy adults, pro-
viding additional support for the safety profile of colostrum ingestion.
Keywords Nutraceutical · Sports nutrition · Food supplement · Prostate cancer
Introduction
Gastrointestinal symptoms including cramps, diarrhea, nau-
sea, and bleeding are commonly reported by long-distance 
runners and athletes undertaking extreme endurance compe-
titions and are likely to be due to a combination of reduced 
splanchnic blood flow, hormonal changes, altered gut perme-
ability, and increased body temperature [1–4]. These athletes 
are also susceptible to increased incidence of symptoms of 
upper respiratory tract infections, especially during periods 
of strenuous exercise training and immediately after com-
petition [5, 6].
Pharmacological options to reduce these problems are 
limited, particularly in competitive athletics, and there 
is, therefore, great interest in the use of natural products. 
One such product, that is already commercially available, 
is bovine colostrum. Colostrum is the first milk produced 
after birth and is particularly rich in immunoglobulins, 
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antimicrobial peptides (e.g., lactoferrin, lactoperoxidase), 
and other bioactive molecules including growth factors such 
as transforming growth factor-beta and IGF-1 [7]. As an 
example, IGF1 levels in bovine colostrum are approximately 
fivefold higher than mature milk [8]. In combination with 
the milk that is subsequently produced, colostrum is impor-
tant for the nutrition, growth, and development of the new-
born infant and contributes to the immunological defense 
of the neonate and in eliminating infection and stimulating 
growth of the neonatal gastrointestinal tract [9]. In adults, 
randomized clinical trials have shown beneficial effects of 
oral colostrum supplementation in reducing NSAID-induced 
and exercise-induced hyperpermeability [10, 11] and reduc-
ing the frequency of upper respiratory symptoms of athletes 
in training [12].
Colostrum is freely available in health food stores and 
via the internet and is taken by normal subjects to maintain 
gut integrity, patients with gut-related injuries and athletes 
to enhance their ability to train successfully. However, the 
world anti-doping agency (WADA) advises athletes against 
taking colostrum for fear of causing a rise in levels of IGF-1 
in the circulation with resulting doping penalties (https ://
www.wada-ama.org). In addition, concerns have been raised 
that if circulatory IGF-1 is raised in response to colostrum 
supplementation, prolonged administration of colostrum 
might stimulate malignancy in distant organs such as pros-
tate cancer which is known to commonly express IGF-1 
receptors [13].
To address these potential concerns, we now present stud-
ies examining the relationship between colostrum ingestion 
and circulatory levels of IGF-1. These studies comprised: 
(1) an analyses of changes in plasma IGF-1 levels follow-
ing short term administration of colostrum; (2) an analy-
ses of changes in IGF-I in stored plasma samples that were 
collected during two placebo-controlled randomized trials 
of longer term bovine colostrum supplementation (1 and 
3 months, respectively) on immune health that were led by 
the authors of the present study [14, 15].
Materials and methods
Subject selection, collection of blood samples, IGF‑1 
assay and test products
All participants were recreationally active males, non-
allergic to dairy products and reported no symptoms of 
infection or taking any medication or dietary supplements 
4 weeks prior to commencement of studies. For all stud-
ies, blood samples were collected into a vacutainer (Bec-
ton–Dickinson, Oxford, UK) containing EDTA, and tubes 
centrifuged at 1500g for 10 min at 4 °C. Plasma was then 
isolated and stored at − 80 °C until analysis. On day of 
assay, plasma samples underwent pre-treatment to release 
IGF-1 from binding proteins and IGF-1 concentration then 
quantified in duplicate using a commercial enzyme-linked 
immunosorbent assay (ELISA, R&D Systems, Abingdon, 
UK) according to manufacturer’s instruction.
For all three studies, effects of powdered bovine colos-
trum, (Neovite UK, London, UK) was compared against 
an isoenergetic/isomacronutrient placebo (compris-
ing skimmed milk powder and milk protein concentrate 
(Marvel, Premier Foods, Thame, UK and My Protein Ltd, 
Cheshire, UK).
Study 1: effect of short‑term bovine colostrum 
supplementation on plasma IGF‑1 in subjects 
undertaking moderate exercise
Design: a double-blind, placebo-controlled, counterbal-
anced, randomized crossover protocol.
Participants: sixteen male subjects (age 25 ± 6 years; 
height 178 ± 6 cm; BM 75.7 ± 7.5 kg).
Protocol: each subject underwent two identical experi-
mental arms, in randomized order, separated by 7 days 
(Fig. 1a). During the 48 h preceding each arm, participants 
abstained from heavy exercise and alcohol and recorded 
their food intake during the 24 h before the first experimen-
tal arm. To standardize their nutritional status, subjects fol-
lowed the same food intake during the 24 h prior to second 
experimental arm.
Subjects reported to the laboratory after an overnight fast 
of at least 10 h. Upon arrival, participants remained seated 
for 10 min prior to collection of a resting baseline (0 h) 
blood sample. Participants then consumed either 30 g of 
bovine colostrum or the isoenergetic/isomacronutrient pla-
cebo (both made up in 300 ml water). Participants undertook 
restful activities (e.g., reading) before collection of second 
blood sample (+ 1 h sample) and then ingested a further 5 g 
of colostrum or placebo mixed in 50 mL water prior to start-
ing 2.5 h of cycling at 15% Δ (~ 55–60% VO
2max ). A final 
dose (5 g) of colostrum or placebo was given 1.25 h into 
the exercise regimen (+ 2.25 h sample) to all participants. 
Participants were permitted diluted cordial (four volumes of 
water to 1 volume of sugar-free cordial at 2 mL/kg of BM) 
every 15 min during the first arm with the pattern of intake 
and total volume consumed being replicated in the second 
arm. One hour after finishing the cycling a third and final 
blood sample (+ 4.5 h) was taken.
Statistical analyses were performed using the statistical 
programmed SPSS (v24.0; IBM Corp., Armonk, NY., USA) 
with statistical significance accepted at p < 0.05. Data were 
checked for normal distribution using the Shapiro–Wilk test. 
A two-factor repeated measures ANOVA (group × time) was 
then carried out.
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Studies 2 an 3: effect of long‑term bovine colostrum 
supplementation (4 and 12 weeks) on plasma IGF‑1 
levels in healthy subjects
Summary of overall design: effects of colostrum administra-
tion on IGF-1 levels were determined using stored plasma 
samples collected from two double-blind, parallel group, 
placebo-controlled, randomized trials. In these trials, colos-
trum had been administered for 4 and 12 weeks with the pri-
mary aim of examining rate of respiratory infection, mucosal 
immunity and blood neutrophil responses [14, 15].
Study 2
Twenty (10 in each arm) individuals aged 28 ± 8 years; 
body mass 79 ± 7 kg participated in the study consisting of 
daily supplementation of 20 g of colostrum or placebo for 
4 weeks. Resting blood samples were collected following 
an overnight fast at the beginning and end of the 4-week 
period [14].
Study 3
Fifty-seven subjects were randomized to receive daily 
supplementation of 20 g of colostrum or placebo (10 g in 
the morning and in the evening before relevant meal) for 
12 weeks. Four subjects had protocol violation (failure to 
take supplementation for full period) and were excluded. 
Those that completed the full protocol comprised 25 indi-
viduals in colostrum arm (age: 30.5 ± 13.8 years, height: 
179.9 ± 6.4 cm, body mass: 77.2 ± 8.9 kg) and 28 subjects 
(age: 31.5 ± 13.2 years, height 178.4 ± 6.6 cm, body mass 
74.5 ± 8.7 kg) in placebo arm. Resting blood samples fol-
lowing an overnight fast were collected at the beginning and 
end of the 12-week period [15].
Statistical analyses
Statistical analyses were performed using SPSS and data 
were checked for normal distribution using the Shapiro–Wilk 
test. A two-factor mixed model ANOVA (group × time) was 
used to determine if the effect of time was different between 
Fig. 1  Effect of short -term 
bovine colostrum or placebo 
supplementation (40 g in total) 
on plasma IGF-1 in subjects 
undertaking moderate exercise 
using a randomized crossover 
design. a Study protocol. b 
Plasma IGF-1 levels found at 
the various stages of the study. 
Individual results are shown. 
No statistically significant dif-
ferences between the two arms 
were seen
A
B
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bovine colostrum (4-week or 12-week supplementation) and 
placebo groups.
Results
Study 1: effect of short‑term bovine colostrum 
supplementation on plasma IGF‑1 in subjects 
undertaking moderate exercise
Results for each individual are shown in Fig. 1b. A two-
factor repeated measures ANOVA (group: p = 0.133, 
group × time interaction: p = 0.166, time p = 0.013) revealed 
a slight non-significant change over time, due to a slight 
rise in both arms at the 1-h time period, but not any signifi-
cant differences in IGF-1 between a total dose of 40 g of 
bovine colostrum (n = 16, baseline: 130 ± 36 ng/ml, + 1 h: 
132 ± 34 ng/ml, + 4.5 h: 126 ± 32 ng/ml) or placebo (n = 16, 
baseline: 133 ± 39 ng/ml, + 1 h: 141 ± 39 ng/ml, + 4.5 h: 
133 ± 39 ng/ml).
Studies 2 and 3: effect of long‑term bovine 
colostrum supplementation (4 and 12 weeks) 
on plasma IGF‑1 levels in healthy subjects
Study 2: 4‑week administration
Compared to placebo, 4 weeks of bovine colostrum (20 g 
per day) revealed no differences in circulating IGF-I between 
placebo and bovine colostrum (two-way mixed ANOVA, 
group: p = 0.584, group × time interaction: p = 0.083, time 
p = 0.243) (Fig. 2a).
Fig. 2  Effect of long-term 
bovine colostrum or placebo 
supplementation on IGF-1 
levels using double-blind, paral-
lel group, placebo-controlled, 
randomised protocols. a IGF-1 
levels in subjects receiving 20 g 
per day for 4 weeks b IGF-1 
levels in subjects receiving 20 g 
per day for 12 weeks. Individual 
results from each subject are 
shown. No statistically signifi-
cant differences between pla-
cebo and colostrum were seen
A
B
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Study 3: 12‑week administration
Compared to placebo, 12 weeks of bovine colostrum (20 g 
per day) supplementation did not lead to changes in circu-
lating IGF-I (two-factor mixed ANOVA, group: p = 0.400, 
group × time interaction: p = 0.498, time p = 0.602) (Fig. 2b).
Discussion
We showed that oral consumption of bovine colostrum (20-
40 g/day), either acutely (1–4.5 h post-ingestion) or chroni-
cally (4–12 weeks) in healthy adult subjects has no influence 
on systemic concentrations of IGF-I.
Growth factors, whether produced by purification or 
using recombinant technology, are increasingly being used 
for a variety of clinical conditions. Examples include recom-
binant human insulin for the treatment of diabetes, erythro-
poietin for renal failure‐induced anemia and interferon for 
viral hepatitis. The use of such factors for ‘hollow organ’ 
gastrointestinal conditions is at a more preliminary stage 
although systemically administered glucagon-like peptide-2 
(GLP-2) for the treatment of short bowel syndrome is now a 
clinically proven, albeit very expensive treatment (estimate 
$200,000 per quality adjusted life year). In addition to cost, 
there are concerns that systemic growth factor administra-
tion may have unwanted side effects such as tumor progres-
sion as many tumors express several growth factor receptors 
and may also cause other unwanted side effects such as fluid 
retention.
In parallel with studies of recombinant peptides for gut 
conditions, there have been several clinical trials examining 
the potential value of bovine colostrum for gastrointestinal 
problems. Use of colostrum rather than a single recombinant 
peptide has the advantages of maintaining potential synergis-
tic activity between the various growth factors within colos-
trum and that its formulation naturally protects its growth 
factor activity to reach more distal regions of the gut in an 
intact biologically active form [16]. These trials suggest that 
colostrum has clinical value for NSAID-induced gut injury 
[9], chemotherapy induced mucositis [17] and inflammatory 
bowel disease [18]. In addition, colostrum may have value 
for reducing symptoms of infective diarrhea [19], possibly 
acting through its specific (antibodies) and general anti-
microbial constituents such as lactoferrin. Colostrum may 
also have value as a sports nutritional supplement to reduce 
the incidence of upper respiratory tract infections during 
training [15] and to reduce the increased gut permeability 
that occurs during heavy exercise [20]. Although there is 
currently insufficient evidence to conclusively establish the 
value of bovine colostrum to enhance performance, it is 
being used increasingly by track and field athletes. Of the 
studies that have been performed, its major value may be in 
the context of athletes undertaking high-intensity training 
and in aiding recovery [21].
In addition to its pharmacological advantages, there is 
currently a demand from the general public for more ‘nat-
ural’ types of products, which are usually considered as 
‘alternative therapy’, but which can possess potent biologi-
cal activity. Products such as these are often termed nutra-
ceuticals (from nutrition and pharmaceuticals) [22].
Although there seems to be many advantages of using 
colostrum at the sports nutrition-functional food interface, 
two main concerns have been raised, especially if taken for 
prolonged periods. The first relates to use as a supplement in 
competitive sports training; The colostrum products used in 
these studies have been certified by a company (HFL Sports 
Science UK, Fordham, Cambridgeshire) that has ISO 17025 
accreditation for testing sports supplements to control con-
tamination with banned substances to ensure compliance 
with WADA and has been shown to not contain any banned 
substances. Nevertheless, because colostrum contains IGF-I, 
WADA advises athletes against taking colostrum for fear of 
causing a rise in the levels of IGF-I in the circulation with 
resulting doping penalties.
Although we are not aware of any clinical data support-
ing this idea, concerns have also been raised that colostrum 
might increase the risk of prostate cancer, as prostate cancer 
cells often express IGF-I receptors and respond to IGF-I 
administration with enhanced cell proliferation and glucose 
consumption. However, the pathophysiological situation is 
more complicated, as administration of IGF-I to noncancer-
ous prostate cells increases basal to luminal differentiation 
[13].
It is for these reasons that there is much interest in 
whether circulatory IGF-I increases in subjects taking colos-
trum. Our initial study attempted to reproduce a standard 
scenario of a person taking standard doses of colostrum in 
combination with undertaking moderate exercise, as occurs 
during sports training. We found no statistically significant 
differences in plasma IGF-I levels in response to colostrum 
versus placebo. The second study examined moderate doses 
of colostrum (10 g twice a day for 4 weeks) reproducing an 
individual who decides to take a short course of colostrum 
supplementation and again found no rise in IGF-I levels in 
either placebo or colostrum group. The third study examined 
the same 20 g/day dose of colostrum for a prolonged period 
(12 weeks) and again, no rise was seen.
Our findings support and extend previous work by 
Coombes et al. who examined changes in plasma IGF-1 
in response to 20–60 g per day of colostrum for 8 weeks 
and found no increase [7]. Similar negative results have 
been reported by others following ingestion of 20 g or 
60 g/day of colostrum or whey, also for 8 weeks [23–25]. 
In contrast, Mero et al. reported that colostrum inges-
tion does increase IGF-I levels [26] although there were 
 European Journal of Nutrition
1 3
methodological and interpretation issues as the only signif-
icant effect seen was comparing the change in IGF-1 levels 
from baseline, due to the placebo arm falling by 18 ng/ml 
and the colostrum-treated group increasing by 28 ng/ml) 
[26]. These changes, therefore, seem to reflect physiologi-
cal variability of IGF-I levels rather than a change due to 
colostrum ingestion, a conclusion supported by our results 
from our study 1. In addition, the Mero study [26] used 
glucose as the placebo rather than a protein containing 
control as used by other groups. This is important in inter-
preting their results, as higher protein intake is associated 
with increased endogenous IGF production [27].
Additional evidence against ingested IGF- I reaching 
the circulation intact comes from studies examining the 
effect of orally administered 125I labeled IGF-I on blood 
IGF-I [28]. These showed that virtually all the 125I present 
in the bloodstream was in a digested fragmentary inactive 
form. This suggests that any change seen in IGF-I levels 
would be more likely to be due to changes in intrinsic pro-
duction rather than due to absorption of colostrum derived 
IGF-I.
In summary, we conclude that ingestion of standard doses 
of colostrum (20–40 g/day) in healthy adult subjects does 
not result in an immediate or long-term increase in circulat-
ing IGF-I levels. This lack of effect is probably due to the 
digestion of the IGF-I by intestinal digestive enzymes. These 
findings provide additional support for the safety profile of 
colostrum ingestion in populations that can benefit from the 
favorable effects of colostrum on gastrointestinal and res-
piratory health.
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